Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 197

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results

Reardon, David A., Akabani, Gamal, Coleman, R. Edward, Friedman, Allan H., Friedman, Henry S., Herndon, James E., McLendon, Roger E., Pegram, Charles N., Provenzale, James M., Quinn, Jennifer A., Rich, Jeremy N., Vredenburgh, James J., Desjardins, Annick, Guruangan, Sri, Badruddoja, Michael, Dowell, Jeanette M., Wong, Terence Z., Zhao, Xiao-Guang, Zalutsky, Michael R., Bigner, Darell D.·2006·Journal of Clinical Oncology

Abstract

Purpose: To assess the efficacy and toxicity of intraresection cavity iodine-131–labeled murine antitenascin monoclonal antibody 81C6 (131 I-m81C6) among recurrent malignant brain tumor patients. Patients and Methods: In this phase II trial, 100 mCi of 131 I-m81C6 was injected directly into the surgically created resection cavity (SCRC) of 43 patients with recurrent malignant glioma (glioblastoma multiforme [GBM], n = 33; anaplastic astrocytoma [AA], n = 6; anaplastic oligodendroglioma [AO], n = 2; gliosarcoma [GS], n = 1; and metastatic adenocarcinoma, n = 1) followed by chemotherapy. Results: With a median follow-up of 172 weeks, 63% and 59% of patients with GBM/GS and AA/AO tumors were alive at 1 year. Median overall survival for patients with GBM/GS and AA/AO tumors was 64 and 99 weeks, respectively. Ten patients (23%) developed acute hematologic toxicity. Five patients (12%) developed acute reversible neurotoxicity. One patient (2%) developed irreversible neurotoxicity. No patients required reoperation for radionecrosis. Conclusion: In this single-institution phase II study, administration of 100 mCi of 131 I-m81C6 to recurrent malignant glioma patients followed by chemotherapy is associated with a median survival that is greater than that of historical controls treated with surgery plus iodine-125 brachytherapy. Furthermore, toxicity was acceptable. Administration of a fixed millicurie dose resulted in a wide range of absorbed radiation doses to the SCRC. We are now conducting a phase II trial, approved by the US Food and Drug Administration, using patient-specific 131 I-m81C6 dosing, to deliver 44 Gy to the SCRC followed by standardized chemotherapy. A phase III multicenter trial with patient-specific dosing is planned.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.03.4082

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 197

Metadata

Authors
Reardon, D. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., Herndon, J. E., McLendon, R. E., Pegram, C. N., Provenzale, J. M., Quinn, J. A., Rich, J. N., Vredenburgh, J. J., Desjardins, A., Guruangan, S., Badruddoja, M., Dowell, J. M., Wong, T. Z., Zhao, X.-G., Zalutsky, M. R., & Bigner, D. D.
Venue
Journal of Clinical Oncology
Published
2006-01-01
Volume
24
Issue
1
Pages
115-122
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2135881288
Cited by
197
References
3
FWCI
7.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results. https://app.cochat.ai/papers/10.1200/jco.2005.03.4082
The paper
Reardon, D. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., Herndon, J. E., McLendon, R. E., Pegram, C. N., Provenzale, J. M., Quinn, J. A., Rich, J. N., Vredenburgh, J. J., Desjardins, A., Guruangan, S., Badruddoja, M., Dowell, J. M., Wong, T. Z., Zhao, X.-G., Zalutsky, M. R., & Bigner, D. D. (2006). Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.03.4082

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.